The Renal Nephropathy research group at the University of Alcalá presents a method of diagnosis of Renal Insufficiency (RI), in all varieties of the disease, that determines the amount of protein related to parathyroid hormone (PTHrP) present in a sample of urine, comparing said amount with at least one reference value and diagnosing RI from said comparison.
The research group seeks companies from the diagnostic medicine, biomedicine or pharmacy sector to establish licensing agreements, collaboration agreements or commercial agreements with technical assistance.
Renal disease can be acute or chronic and both progress with Renal Insufficiency (RI) and ultimately death.
In recent years the search and identification of new RI biomarkers molecules, particularly in urine, has intensified.
The present invention describes the diagnosis of acute or chronic Renal Insufficiency by urinary quantification of the protein related to Parathyroid Hormone PTHrP, comparing that amount with at least one reference value and diagnosing RI based on that comparison.
PTHrP is normally undetectable in organic fluids of a healthy individual, so that its mere presence already serves as a marker of disease. Thus, the finding of an increased urinary PTHrP value in comparison to the value found in healthy individuals results in a biomarker indicative of acute or chronic IR.
The most viable method is to analyze urine samples using Western Blotting of proteins using a specific monoclonal antibody that recognizes the protein related to Parathormone (PTHrP). The presence of a single band, in addition to demonstrating the specificity of the methodology used, allows to use a simpler detection technique such as the dot blot.
In order to quantify the above analysis, a preferred embodiment of the method of the invention is that the reference value is obtained from a control sample. And that the individual from which the urine sample is taken is a mammal, preferably a human.
The present invention, with respect to the state of the art, avoids the invasive extraction of the necessary biological sample and offers a diagnostic value prior to the symptoms of Chronic Renal Failure (CRF) and Acute Renal Failure (ARF), and to the functional disorders on which the main diagnostic methods currently available are based.
The biomarker described in the present invention has the following major clinical advantages over other known biomarkers:
- First, the method only requires the analysis of an isolated sample of urine to make possible the diagnosis of RI
- Second, while the diagnostic utility of known biomarkers in urine is limited to acute renal failure (ARF), the present invention further allows the diagnosis of chronic renal failure (CRF)
- Since the method described in this invention only requires the analysis of an isolated urine sample, it makes it possible to diagnose acute or chronic RI in isolated samples from patients' urine or in single samples, and even in old urine samples allowing the retrospective diagnosis even in the absence of serum or plasma.
- The presence of a unique band, in addition to demonstrating the specificity of the methodology used, allows the use of a simpler detection technique such as the dot blot.
Intellectual property status
Patent number : The patent has been granted under the publication number of 2403755
Where : OEPM
Current development status
Commercially available technologies
Desired business relationship
New technology applications
Other : The group seeks to achieve patent licensing agreements, collaboration agreements and commercial agreements with technical assistance, with companies in the medical, biomedical or pharmaceutical sectors.